fish steak recipe
US Energy Infra Firms Set for Record Gains as AI Power Demand Soars
Pete Carroll wants to mentor Caleb Williams, coach Bears and teach at USC? He's a young 73.Nick Kern came off the bench for 20 points and 13 rebounds as Penn State remained unbeaten with an 85-66 thumping of Fordham in a semifinal of the Sunshine Slam on Monday in Daytona Beach, Fla. The Nittany Lions (6-0), who will play either San Francisco or Clemson for the tournament title on Tuesday, put four other players in double figures. Zach Hicks scored 16 points, while Puff Johnson added 15. Ace Baldwin and Yanic Konan Niederhauser each chipped in 12 points. Penn State sank nearly 53 percent of its field goal attempts and earned a 38-30 advantage on the boards, more than enough to offset missing 12 of its 32 foul shots. Four players reached double figures for the Rams (3-4), led by 15 points apiece from Jackie Johnson III and reserve Joshua Rivera. Romad Dean and Jahmere Tripp each added 13. Fordham was as close as 56-49 after Tripp made a layup with 14:25 left in the game. But the Nittany Lions responded with a 16-1 run, capped with a layup by Kern for a 22-point lead at the 9:33 mark, and they never looked back. The main storyline prior to tipoff was whether Penn State could continue its torrid early start that saw it come into the day leading Division I in steals and ranked second in scoring at 98.2 points per game. The Nittany Lions certainly played to their billing for most of the first half, establishing a 21-8 lead at the 10:08 mark via Hicks' three-point play. Fordham predictably struggled early with the pressure defense, committing four turnovers in the first four minutes. But the Rams got their bearings over the last 10 minutes and made some shots. They got as close as four on two occasions late in the half before Penn State pushed the lead to 42-34 at the half. The officials were busy in the half, calling 23 fouls and administering 27 free throws. --Field Level Media
Afraid of losing the US-Canada trade pact, Mexico alters its laws and removes Chinese parts‘Dumpster fire’ banner flies over New York Giants game at MetLife StadiumChefs Warehouse Stock Hits All-Time High at $44.66 Amid Robust Growth
Natixis Advisors LLC raised its holdings in shares of Blue Owl Capital Inc. ( NYSE:OWL – Free Report ) by 6.8% in the 3rd quarter, Holdings Channel reports. The firm owned 246,878 shares of the company’s stock after purchasing an additional 15,701 shares during the quarter. Natixis Advisors LLC’s holdings in Blue Owl Capital were worth $4,780,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Other institutional investors have also recently added to or reduced their stakes in the company. Transcendent Capital Group LLC bought a new position in shares of Blue Owl Capital during the first quarter worth about $26,000. ORG Partners LLC bought a new position in shares of Blue Owl Capital during the second quarter worth about $32,000. ORG Wealth Partners LLC bought a new position in shares of Blue Owl Capital during the third quarter worth about $32,000. Family Firm Inc. bought a new position in shares of Blue Owl Capital during the second quarter worth about $40,000. Finally, Rothschild Investment LLC bought a new position in shares of Blue Owl Capital during the second quarter worth about $45,000. Institutional investors own 35.85% of the company’s stock. Analyst Upgrades and Downgrades Several equities analysts have recently commented on the stock. Wells Fargo & Company upped their price target on shares of Blue Owl Capital from $18.50 to $21.00 and gave the stock an “equal weight” rating in a research report on Wednesday, October 9th. Oppenheimer upped their price objective on shares of Blue Owl Capital from $21.00 to $24.00 and gave the stock an “outperform” rating in a report on Wednesday, October 16th. Evercore ISI upped their price objective on shares of Blue Owl Capital from $21.00 to $22.00 and gave the stock an “outperform” rating in a report on Tuesday, October 8th. Deutsche Bank Aktiengesellschaft upped their price objective on shares of Blue Owl Capital from $23.00 to $24.00 and gave the stock a “buy” rating in a report on Friday, November 1st. Finally, Piper Sandler upped their price objective on shares of Blue Owl Capital from $23.00 to $25.00 and gave the stock an “overweight” rating in a report on Friday, November 1st. Four analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $22.31. Blue Owl Capital Stock Performance Shares of NYSE:OWL opened at $24.55 on Friday. Blue Owl Capital Inc. has a twelve month low of $13.01 and a twelve month high of $24.70. The firm has a market cap of $36.67 billion, a PE ratio of 144.42, a price-to-earnings-growth ratio of 1.57 and a beta of 1.14. The business has a fifty day moving average of $21.55 and a 200-day moving average of $19.14. Blue Owl Capital ( NYSE:OWL – Get Free Report ) last announced its quarterly earnings data on Thursday, October 31st. The company reported $0.20 EPS for the quarter, hitting analysts’ consensus estimates of $0.20. Blue Owl Capital had a return on equity of 19.98% and a net margin of 4.95%. The firm had revenue of $600.88 million during the quarter, compared to analyst estimates of $565.93 million. During the same period last year, the company earned $0.16 earnings per share. On average, analysts anticipate that Blue Owl Capital Inc. will post 0.78 EPS for the current fiscal year. Blue Owl Capital Dividend Announcement The company also recently announced a quarterly dividend, which was paid on Friday, November 22nd. Shareholders of record on Monday, November 11th were paid a $0.18 dividend. This represents a $0.72 annualized dividend and a yield of 2.93%. The ex-dividend date was Monday, November 11th. Blue Owl Capital’s payout ratio is 423.55%. About Blue Owl Capital ( Free Report ) Blue Owl Capital Inc operates as an asset manager in the United States. The company offers permanent capital base solutions that enables it to offer holistic framework of capital solutions to middle market companies, large alternative asset managers, and corporate real estate owners and tenants. It also provides direct lending products that offer private credit products comprising diversified, technology, first lien, and opportunistic lending to middle-market companies; liquid credit; GP strategic capital products, which offers capital solutions, including GP minority stakes, GP debt financing, and professional sports minority stakes; and real estate products that focuses on acquiring triple net lease real estate by investment grade or creditworthy tenants. See Also Want to see what other hedge funds are holding OWL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Blue Owl Capital Inc. ( NYSE:OWL – Free Report ). Receive News & Ratings for Blue Owl Capital Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Blue Owl Capital and related companies with MarketBeat.com's FREE daily email newsletter .
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $12.46 Million Stock Position in Five Below, Inc. (NASDAQ:FIVE)
-Drives Continuous Innovation in Specialized Diagnostics to Power Patient Care- BEDFORD, Mass., Dec. 3, 2024 /PRNewswire/ -- Werfen today announced the opening of a new building, expanding its capabilities for innovation in Specialized Diagnostics, at its Hemostasis and Acute Care Diagnostics Technology Center, in Bedford, MA, USA. Werfen's Chairman, Marc Rubiralta, along with other senior leaders from Werfen, will host a ribbon-cutting ceremony at the Bedford campus. The new building adds 105,000 additional square feet, and represents an investment of more than $50 million. The Hemostasis and Acute Care Diagnostics Technology Center is the largest within Werfen's global network. In 2009, Werfen established its Technology Center in Bedford with 600 employees. As business success accelerated, the Company continued to invest in infrastructure to ensure state-of-the art operations, and grow its employee population. Today, the employee base at this location has increased to more than 1,200 strong, and with the new building, has the potential capacity of up to 2,000 employees, allowing growth of its innovation program for several years to come. "Our expanded Technology Center represents the commitment of our shareholders and the Company to the Commonwealth of Massachusetts, as the optimal hub for healthcare innovation, with some of the finest academic and research institutions, and scientists, in the world," said Giovanni Russi, Chief Operating Officer, Hemostasis and Acute Care Diagnostics, at Werfen. "Bedford, with close proximity to Boston, is an ideal location for our continued long-term investments in the research, development and manufacturing of Specialized Diagnostics." Werfen's success is based on the positive impact its Specialized Diagnostic solutions have on clinicians and the patients they care for, all over the world. The Company's areas of clinical focus include: Hemostasis, Acute Care, Transfusion, Autoimmunity and Transplant. Today, Werfen is comprised of more than 7,000 employees globally, with approximately 55% based in the US, and 15% in Bedford. Werfen ( www.werfen.com ), founded in 1966, is a worldwide developer, manufacturer and distributor of specialized diagnostic instruments, related reagents, automation workcells, and data management solutions for use primarily in hospitals and independent clinical laboratories. The Company's clinical areas of focus include Hemostasis, Acute Care, Transfusion, Autoimmunity, and Transplant. Werfen's Acute Care portfolio includes the new GEM Premier 7000 with iQM3, the GEM® PremierTM 5000 with iQM®2, GEM Premier 3500 system with iQM, GEM Premier ChemSTATTM system, ROTEM® viscoelastic testing systems, HemochronTM systems, VerifyNowTM platelet function testing system, and AvoximeterTM1000 CO-Oximeter, GEMweb® Plus 500 Custom Connectivity and GEMweb Live. The Hemostasis portfolio includes ACL TOP® Family 50 Series and ACL TOP Family Hemostasis Testing Systems, ACL AcuStar® system, ACL Elite® systems, HemoCellTM Specialized Lab Automation, HemoHubTM Intelligent Data Manager, along with the comprehensive line of HemosIL® assays. The Werfen logo is a trademark of Werfen. GEM, Premier, GEM Premier ChemSTAT, GEMweb, iQM, ChemSTAT, HemosIL, ACL, ACL TOP, ACL Elite, ACL AcuStar, ReadiPlasTin, RecombiPlasTin, SynthASil, SynthAFax, ROTEM, Hemochron, VerifyNow and Avoximeter are trademarks of Instrumentation Laboratory Company, d.b.a Werfen, and/or one of its subsidiaries or parent companies and may be registered in the United States Patent and Trademark Office and in other jurisdictions. All other product names, company names, marks, logos, and symbols are trademarks of their respective owners. View original content: https://www.prnewswire.com/news-releases/werfen-expands-hemostasis-and-acute-care-diagnostics-technology-center-in-bedford-ma-302320246.html SOURCE Werfen